6000K Bulbs LED H8 H11 2pcs White Lamp Lights Fog Driving Car Lens Projector COB Car & Truck LED Light Bulbs


  1. Home
  2. 6000K Bulbs LED H8 H11 2pcs White Lamp Lights Fog Driving Car Lens Projector COB
  1. facebook
  2. twitter
  3. linkedin
  4. pinterest
2pcs H11 H8 LED Bulbs 6000K White COB Projector Lens Car Driving Fog Lights Lamp
Condition: New Brand:

Unbranded

Type: H11 H8 7.5W COB LED Manufacturer Part Number:

Does Not Apply

To Fit: Fog lights Only (Not suitable for headlights) Placement on Vehicle: Front
Bulb Color: 6000K White Warranty: 90 Day
Wattage: 7.5W Lifetime: 30,000 Hours
Voltage: 12V Lumens: 600-650 Lm one bulb
Number of Bulbs: 2pcs UPC:

Does not apply

published on tue nov 09 2021

6000K Bulbs LED H8 H11 2pcs White Lamp Lights Fog Driving Car Lens Projector COB Car & Truck LED Light Bulbs

gandhi, s., klein, j., robertson, a., pena-hernandez, m. a.,

6000K Bulbs LED H8 H11 2pcs White Lamp Lights Fog Driving Car Lens Projector COB Car & Truck LED Light Bulbs

lin, m. j., roychoudhury, p., lu, p., fournier, j., ferguson, d., mohamed bakhash, s. a., muenker, m. c., srivathsan, a., wunder, e. a., kerantzas, n., wang, w., pyle, a., wilen, c. b., ogbuagu, o., greninger ,, a. l., iwasaki, a., schulz, w. l., ko, a. i.

sars-cov-2 remdesivir resistance mutations have been generated in vitro but have not been reported in patients receiving treatment with the antiviral agent. we present a case of an immunocompromised patient with acquired b-cell deficiency who developed an indolent, protracted course of sars-cov-2 infection. remdesivir therapy alleviated symptoms and produced a transient virologic response, but her course was complicated by recrudescence of high-grade viral shedding. whole genome sequencing identified a mutation, e802d, in the nsp12 rna-dependent rna polymerase which was not present in pre-treatment specimens. in vitro experiments demonstrated that the mutation conferred a ~6-fold increase in remdesivir ic50 but resulted in a fitness cost in the absence of remdesivir. sustained clinical and virologic response was achieved after treatment with casirivimab-imdevimab. although the fitness cost observed in vitro may limit the risk posed by e802d,

, this case illustrates the importance of monitoring for remdesivir resistance and the potential benefit of combinatorial therapies in immunocompromised patients with sars-cov-2 infection.

509
1.2k
EVGENIA.RU RSS